PPR-143 - New indication, more use: Amplifying early positive signals for tirzepatide in Spain

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: PPR-143
• By: JIMENEZ-SERRANIA, Maria-Isabel (Miguel De Cervantes European University (UEMC), Spain)
• Co-author(s): Prof Maria-Isabel Jimenez-Serrania (Miguel De Cervantes European University (UEMC), Valladolid, Spain)
  Ms Sara-Maria Martinez-Gonzalez (Miguel De Cervantes European University (UEMC), Valladolid, Spain)
  
• Abstract:

  Introduction: Tirzepatide is a new dual GIP/GLP-1 receptor agonist, initially approved in Europe for the treatment of Type 2 Diabetes Mellitus and more recently for weight loss in adults with overweight and obesity. This active ingredient has a particular administration pattern. The starting dose for both indications is 2.5 mg once weekly, after 4 ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login